• "Biotech where science and spirit meet..."
Skip to content

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion

– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price – Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular…

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain

“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University of Virginia in Charlottesville. “These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing,” he added. More at:…

Marijuana producer Organigram stock soars 30% as sales double

Organigram Holdings Inc. stock soared 30% during extended trading Tuesday, as the Canadian weed company reported fiscal first-quarter revenue that jumped two-fold, beating Wall Street estimates. Net revenue rose to C$25.2 million ($19.3 million) from C$12.4 million a year ago, which beat the consensus estimate of C$21 million, according to analysts polled by FactSet. The…

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval. More at:  https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for Investigational Cellular Treatment

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is an opportunity to make investor…

12 tips for safe social networking

Social media is a fantastic development in human communications.  However, as with any technology, security should not be an afterthought.  Here is a very good list of simple security steps everyone should consider. https://www.networkworld.com/article/2870409/12–tips-for-safe-social-networking.html#slide4

Vote BEFORE 5pm ET TODAY for our biotechnology client Treventis Corporation in the Buzz of BIO contest!

How to vote: 1. Go here – https://convention.bio.org/buzzofbio-vote/  2. Complete each field on the right side of the page 3. Select Treventis Corporation under Technologies of Tomorrow 4. Hit submit

Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

UPDATED: Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads   More at https://endpts.com/biogens-alzheimers-drug-aducanumab-implodes-in-a-phiii-disaster/ 

Social Media is About Content Marketing!

This is a great article about Social Media and how business can and should work with it. As I have advocated, not ads – content content content. https://www.entrepreneur.com/amphtml/330032

How elephants avoid cancer

Elephants have evolved extra copies of a gene that fights tumour cells, according to two independent studies1, 2 — offering an explanation for why the animals so rarely develop cancer. Why elephants do not get cancer is a famous conundrum that was posed — in a different form — by epidemiologist Richard Peto of the University of Oxford, UK,…